Close Menu

licensing agreement

The pace of development for CRISPR-based infectious disease assays increased as the pandemic progressed, more funding became available, and collaboration accelerated. 

Basel, Switzerland-based Lonza will be able to use Arbor's proprietary CRISPR technology in its bioproduction products and services.

Oncocyte will receive upfront cash payments after transferring and installing DetermaRx, in addition to certain tests after it achieves inclusion in the US Comprehensive Cancer Network.

The deal complements rights Sherlock already holds from the Broad Institute, which developed Sherlock's platform.

Sanyou will use the cell line in the development of preclinical antibody drug projects and to support its customers' human biotherapeutic products.

Vivlion, which also holds a license to Goethe University Frankfurt's CRISPR technology, will use the license to offer R&D reagents and screening services.

TwinStrand's duplex sequencing correction technology can detect ultra-low frequency DNA mutations that are otherwise often obscured by technical noise.

The Sydney, Australia-based firm has licensed a single biomarker which it plans to develop into a test for triaging COVID-19 patients.

Qiagen can now sell Phase's proprietary proximity-ligation technology for chromatin conformational analysis research in the US.

Under the agreement, Genetron gains exclusive rights to develop and commercialize minimal residual disease assays using ImmuQuad's immunogenomics technology.

Pages

Politico notes that the Biden Administration has not yet nominated a permanent Food and Drug Administration commissioner. 

Anthony Fauci also informed the World Health Organization executive board that the US would be joining the COVAX initiative, according to CNBC.

A new preprint suggests some SARS-CoV-2 variants could affect the effectiveness of current vaccines, the Associated Press reports.

In Nature this week: Australian lungfish provides details on the movement of vertebrate life from water to land, and more.